Current Report Filing (8-k)
14 März 2023 - 01:43PM
Edgar (US Regulatory)
0001000694 false 0001000694 2023-03-14
2023-03-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 14, 2023
NOVAVAX, INC.
(Exact name of registrant as specified in charter)
Delaware |
|
0-26770 |
|
22-2816046 |
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File
Number) |
|
(I.R.S. Employer
Identification No.)
|
21 Firstfield Road
Gaithersburg,
Maryland
20878
(Address of Principal Executive Offices, including Zip
Code)
(240)
268-2000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
¨ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
|
|
¨ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
Title of
each class |
|
Trading
Symbol(s) |
|
Name of
each exchange on which
registered |
Common Stock, Par Value $0.01 per share |
|
NVAX |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ¨
Item 7.01. Regulation FD Disclosure.
Novavax, Inc. (the “Company”) confirms that it maintains banking
relationships with several large financial institutions and that it
does not hold any deposits or securities or maintain any accounts
at Silicon Valley Bank. The Company continues to monitor potential
broader risk across the banking sector.
The information contained in this Current Report on Form 8-K is
being furnished and shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of
that Section and shall not be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such filing
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
Novavax,
Inc. |
|
|
|
Date: March 14, 2023 |
By: |
/s/ John A. Herrmann
III |
|
Name: |
John A. Herrmann III |
|
Title: |
Executive Vice President, Chief Legal Officer and Corporate
Secretary |
Novavax (NASDAQ:NVAX)
Historical Stock Chart
Von Mai 2023 bis Jun 2023
Novavax (NASDAQ:NVAX)
Historical Stock Chart
Von Jun 2022 bis Jun 2023